CN105343596A - Pharmaceutical preparation for controlling atherosclerosis and its application - Google Patents
Pharmaceutical preparation for controlling atherosclerosis and its application Download PDFInfo
- Publication number
- CN105343596A CN105343596A CN201510774119.9A CN201510774119A CN105343596A CN 105343596 A CN105343596 A CN 105343596A CN 201510774119 A CN201510774119 A CN 201510774119A CN 105343596 A CN105343596 A CN 105343596A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical preparation
- chinese medicinal
- traditional chinese
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a pharmaceutical preparation for controlling atherosclerosis and its application. The preparation comprises an ingredient component and pharmaceutically acceptable auxiliaries. The active ingredient is prepared by means of water extraction and alcohol precipitation from following traditional Chinese medicinal materials in parts by weight: Ramulus Uncariae Cum Uncis 9-15 parts, Zaocys 9-15 parts, Rhizoma Cibotii 12-20 parts, Rhizoma Belamcandae 6-12 parts, Spina Gleditsiae 6-12 parts, Stigmata Maydis 21-33 parts, Herba Speranskiae Tuberculatae 18-30 parts, Cortex Acanthopanacis 5-10 parts, and Thallus Laminariae 6-12 parts. The pharmaceutical preparation of the invention is significantly capable of improving the pathological degree of atherosclerosis and treating both root causes and symptoms with low toxic or side effect.
Description
Technical field
The invention belongs to medical art, prevent and treat atherosclerotic pharmaceutical preparation and application thereof in particular to one.
Background technology
Cardiovascular and cerebrovascular disease is lethal and to disable the highest disease at present, and atherosclerosis (Atherosclerosis, AS) be the main cause of disease causing cardiovascular and cerebrovascular disease, therefore prevent and treat the generation that atherosclerosis then fundamentally can reduce cardiovascular and cerebrovascular disease energetically.Atherosclerosis is clinical common vascular lesion, pathological study confirms, many factors causes ductus arteriosus wall hardeningly to thicken, flexibility decrease and then cause vessel lumen to narrow, thus the blood affecting brain and limbs supplies, affect the function at each position, severe patient even causes limb function to be lost or death.Content clinically usually through blood fat, arterial wall proteins, polysaccharide component chondroitin sulfate, dermatan sulfate is diagnosed and state of illness monitoring atherosclerosis.
At present, treat atherosclerotic method and comprise operative treatment, western medicine and treatment by Chinese herbs.But atherosclerosis is apt to occur in old people, operation wound is large, is unfavorable for the recovery of patient, and operation costly.And treat atherosclerotic Western medicine and mainly comprise following several class: 1, Statins is to reduce the fat regulation medicine of triglyceride and low density lipoprotein, LDL; 2, the antiplatelet medicine that sticks and assemble; 3, thrombus dissolving and anticoagulant; 4 for the symptomatic treatment medicine of ischemia symptom as the vasodilation applied and beta-blocker etc. during treatment angina pectoris; These Western medicine often cause untoward reaction, are especially not suitable for long-term prescription.
Summary of the invention
For the deficiency of operation and the existence of the therapeutic modality such as Western medicine, the object of the present invention is to provide a kind of evident in efficacy, pure Chinese medicinal preparation that toxic and side effects is low and application thereof.This pharmaceutical preparation is prepared from using Chinese crude drug according to a certain percentage as raw material, prevents and treats atherosclerotic curative effect highly significant, few side effects and cheap.
Particularly, the object of the invention is to realize according to following technical scheme:
The atherosclerotic pharmaceutical preparation of a kind of control, be made up of adjuvant acceptable on active component and pharmaceutics, wherein said active component is prepared from through decoction and alcohol sedimentation technique extraction by the traditional Chinese medicinal material raw materials of following weight portion: Ramulus Uncariae Cum Uncis 9-15 part, Zaocys 9-15 part, Rhizoma Cibotii 12-20 part, Rhizoma Belamcandae 6-12 part, Spina Gleditsiae 6-12 part, Stigma Maydis 21-33 part, Herba speranskiae tuberculatae 18-30 part, Cortex Acanthopancis 5-10 part, Thallus Laminariae (Thallus Eckloniae) 6-12 part.
Preferably, the atherosclerotic pharmaceutical preparation of control described above, wherein said active component is prepared from through decoction and alcohol sedimentation technique extraction by the traditional Chinese medicinal material raw materials of following weight portion: Ramulus Uncariae Cum Uncis 11-13 part, Zaocys 11-13 part, Rhizoma Cibotii 15-18 part, Rhizoma Belamcandae 8-10 part, Spina Gleditsiae 8-10 part, Stigma Maydis 25-28 part, Herba speranskiae tuberculatae 22-25 part, Cortex Acanthopancis 6-8 part, Thallus Laminariae (Thallus Eckloniae) 8-10 part.
In a most preferred embodiment of the present invention, the atherosclerotic pharmaceutical preparation of control described above, wherein said active component is prepared from through decoction and alcohol sedimentation technique extraction by the traditional Chinese medicinal material raw materials of following weight portion: Ramulus Uncariae Cum Uncis 12 parts, Zaocys 12 parts, Rhizoma Cibotii 16 parts, Rhizoma Belamcandae 9 parts, Spina Gleditsiae 9 parts, Stigma Maydis 26 parts, Herba speranskiae tuberculatae 23 parts, Cortex Acanthopancis 7 parts, 9 parts, Thallus Laminariae (Thallus Eckloniae).
It should be noted that, the traditional Chinese medicinal material raw materials that pharmaceutical preparation of the present invention is adopted in the preparation has following source: the dry stem and branch with belt hook of Maguireothamnus speciosus Ramulus Uncariae macrophyllae UncariamacrophyllaWall. selected by Ramulus Uncariae Cum Uncis.Zaocys selects Colubridae animal Zaocys Zaocysdhumnades(Cantor) dry body.Rhizoma Cibotii selects Dicksoniaceae plant Rhizoma Cibotii Cibotiumbarometz(L.) dry rhizome of J.Sm..Rhizoma Belamcandae selects irides Rhizoma Belamcandae Belamcandachinensis(L.) dry rhizome of DC..Spina Gleditsiae selects the dry Spina jujubae of leguminous plant Fructus Gleditsia GleditsiasinensisLam..Stigma Maydis selects dry style and the fresh idea of grass family Zea plant Zea mays ZeamaysL..Herba speranskiae tuberculatae selects Euphorbiaceae Speranskia plant speranskia tuberculata Speranskiatuberculata(Bunge) the dry herb of Baill..Cortex Acanthopancis selects the dry root bark of Araliaceae acanthopanax gracilistylus AcanthopanaxgracilistylusW.W.Smith.Thallus Laminariae (Thallus Eckloniae) selects the dry herb of Zosteraceae plant Zostera marina.
The atherosclerotic pharmaceutical preparation of control of the present invention can select following preparation technology: take Chinese medicine extract, add filler, disintegrating agent and binding agent mixing after soft material processed, cross 16-32 mesh sieve wet granular, wet granular is fully dry in 45-60 DEG C, granule is obtained after dry for gained granule and lubricant being mixed, or tabletting or filled capsules shell after dry for gained granule and lubricant are mixed, or capsule.
The present inventor for experimental subject, passes through VD with the healthy rat at 24 monthly ages
3induce the method establishment of feeding in conjunction with high fat experimental atherosclerosis in rats disease model, use medicine of the present invention to treat, and compare with regard to blood fat and arterial wall proteins polysaccharide component chondroitin sulfate, dermatan sulfate content etc. with first two groups.Data shows, medicinal application of the present invention is in the treatment of experimental atherosclerosis in rats, although short-term can not improve the blood fat of rat, but treatment group rat artery wall-held protein polysaccharide component chondroitin sulfate, dermatan sulfate content significantly reduce, this illustrates that the present invention significantly can improve the atherosclerotic lesion degree of rat.Therefore, second object of the present invention is to provide a kind of new medical use, that is: above-mentioned traditional Chinese medicinal material raw materials compositions is purposes in the atherosclerotic medicine of preparation control.
Compared with prior art, the present invention proposes the atherosclerotic Chinese medicine thinking of a kind of control newly, the medicine obtained according to this treatment thoughts can significantly improve atherosclerotic lesion degree, and the treatment for atherosclerotic has the advantages such as curative effect is obvious, treating both the principal and secondary aspects of a disease, toxic and side effects are little.
Detailed description of the invention
Below the concrete preparation example of Chinese medicine extract of the present invention and pharmaceutical preparation, and the effect test example of Chinese medicine extract, technical scheme of the present invention and technique effect are further explained and are described.But protection scope of the present invention is not limited to these embodiments.Every do not deviate from the present invention's design change or equivalent substituting include within protection scope of the present invention.
embodiment 1: the preparation of Chinese medicine dried cream powder
Take Ramulus Uncariae Cum Uncis 1.2kg, Zaocys 1.2kg, Rhizoma Cibotii 1.6kg, Rhizoma Belamcandae 0.9kg, Spina Gleditsiae 0.9kg, Stigma Maydis 2.6kg, Herba speranskiae tuberculatae 2.3kg, Cortex Acanthopancis 0.7kg and Thallus Laminariae (Thallus Eckloniae) 0.9kg merges, decoct with water twice, first time adds purified water 150L, decoct 2h, second time adds purified water 130L, decoct 1.5h, collecting decoction, 0.08MPa, when being evaporated to 70 DEG C at 70 DEG C, relative density is 1.15, adding 95% ethanol makes alcohol content reach 75% (v/v), stir, hold over night, filter, filtrate is at 0.08MPa, under 65 DEG C of conditions, concentrating under reduced pressure one-tenth is the extractum of 1.25 to relative density when 65 DEG C, extractum is put in stainless steel disc, vacuum drying (less than 60 DEG C) becomes dry cream, pulverize.
embodiment 2: the preparation of Chinese medicinal tablet
Take Chinese medicine extract dry powder (being prepared from by the Recipe of embodiment 1) 0.5kg, cross 100 mesh sieves, then added the dextrin 1.3kg of 80 mesh sieves, microcrystalline Cellulose 0.7kg, mix homogeneously, alcoholic solution using appropriate 75%, as binding agent, adopts wet granulation, namely crosses 32 mesh sieve wet granulars, wet granular is fully dry in 45-60 DEG C, granulate, dry granule adds Pulvis Talci 20g, mix homogeneously, direct compression, obtains Chinese medicinal tablet.
embodiment 3: Chinese medicine dried cream powder is to the Therapy study of Atherosclerosis Model mice
Choose the healthy rat 40 at 24 monthly ages, weight 320-360g, is divided into three groups: normal group (11), model group (14), treatment group (15), male and female half and half.Normal rats uses common feedstuff to feed.Model group and treatment group rat make Atherosclerosis Model as follows: first lumbar injection vitamin D
3(7 × 10
5iU/kg, divides 4 times, injects 1 time every 2d), then feeding high lipid food, adds 1% cholesterol, 0.5% sodium cholate, 0.1% thiamazole, 5% Adeps Sus domestica in Rat Standard feed formula, and 93.4% is normal diet.By cleaning grade animal feeding, drinking purified, the whole modeling cycle is 8 weeks.Randomly draw blank group 1 after 8 weeks in modeling, model group 2, treatment group 3, observes aortal morphological changes of various tissue components, to observe atherosclerosis of aorta pathological changes for standard determination modeling success.Subsequently, normal group and model group do not use Drug therapy, only give common feedstuff and drinking-water.Treatment group gavage gives Chinese medicine dried cream powder 125mg/kg prepared by above-described embodiment 1.Each group every day gastric infusion 1 time, administration 45d altogether.After administration terminates, get experimental rat and adopt etherization, extract its heart to the aortic blood every between flesh, detect serum total cholesterol and the low density lipoprotein, LDL of rat.In addition, get aorta, the capable pathological section of coronary artery, carry out the arterial wall proteins polysaccharide component chondroitin sulfate of rat, the detection of dermatan sulfate content.
Treatment 45d after, the blood fat situation of experimental subject is detected and is compared, blood T-CHOL, low density lipoprotein, LDL relatively in treatment group similar with model group, without the significance difference opposite sex (
p> 0.05); And two groups are all significantly higher than normal group, have the pole significance difference opposite sex (
p< 0.01).Concrete test data is as shown in table l.
Table 1 respectively group experimental subject blood fat compares
| Group | Sample size | T-CHOL (mmol/L) | Low density lipoprotein, LDL (mmol/L) |
| Normal group | 10 | 13.14±4.22 | 8.37±2.28 |
| Model group | 12 | 23.49±3.39** | 15.72±1.30** |
| Treatment group | 12 | 23.15±4.60 | 16.06±1.91 |
Model group compares with normal group,
* p< 0.05,
* p< 0.01;
Treatment group compares with model group,
$ p< 0.05,
$$ p< 0.01.
The tremulous pulse pathological section result of experimental subject is studied, arterial wall proteins polysaccharide component chondroitin sulfate, dermatan sulfate content relatively in, treatment group is similar to normal group, without the significance difference opposite sex (
p> 0.05); And two groups are all remarkable in model group, have the pole significance difference opposite sex (
p< 0.01).Concrete test data is as shown in table 2.
Table 2 is group experimental subject pathological section results contrast respectively
| Group | Sample size | Chondroitin sulfate | Dermatan sulfate |
| Normal group | 10 | 22.17±1.14 | 15.70±1.62 |
| Model group | 12 | 31.52±1.01 ** | 19.63±1.81 ** |
| Treatment group | 12 | 22.40±10.83 ￥￥ | 14.59±1.67 ￥￥ |
Model group compares with normal group,
* p< 0.05,
* p< 0.01;
Treatment group compares with model group,
$ p< 0.05,
$$ p< 0.01.
Claims (5)
1. the atherosclerotic pharmaceutical preparation of control, be made up of adjuvant acceptable on active component and pharmaceutics, it is characterized in that, described active component is prepared from through decoction and alcohol sedimentation technique extraction by the traditional Chinese medicinal material raw materials of following weight portion: Ramulus Uncariae Cum Uncis 9-15 part, Zaocys 9-15 part, Rhizoma Cibotii 12-20 part, Rhizoma Belamcandae 6-12 part, Spina Gleditsiae 6-12 part, Stigma Maydis 21-33 part, Herba speranskiae tuberculatae 18-30 part, Cortex Acanthopancis 5-10 part, Thallus Laminariae (Thallus Eckloniae) 6-12 part.
2. prevent and treat atherosclerotic pharmaceutical preparation according to claim 1, it is characterized in that, described active component is prepared from through decoction and alcohol sedimentation technique extraction by the traditional Chinese medicinal material raw materials of following weight portion: Ramulus Uncariae Cum Uncis 11-13 part, Zaocys 11-13 part, Rhizoma Cibotii 15-18 part, Rhizoma Belamcandae 8-10 part, Spina Gleditsiae 8-10 part, Stigma Maydis 25-28 part, Herba speranskiae tuberculatae 22-25 part, Cortex Acanthopancis 6-8 part, Thallus Laminariae (Thallus Eckloniae) 8-10 part.
3. prevent and treat atherosclerotic pharmaceutical preparation according to claim 2, it is characterized in that, described active component is prepared from through decoction and alcohol sedimentation technique extraction by the traditional Chinese medicinal material raw materials of following weight portion: Ramulus Uncariae Cum Uncis 12 parts, Zaocys 12 parts, Rhizoma Cibotii 16 parts, Rhizoma Belamcandae 9 parts, Spina Gleditsiae 9 parts, Stigma Maydis 26 parts, Herba speranskiae tuberculatae 23 parts, Cortex Acanthopancis 7 parts, 9 parts, Thallus Laminariae (Thallus Eckloniae).
4. according to any one of claim 1-3, prevent and treat atherosclerotic pharmaceutical preparation, it is characterized in that, described pharmaceutical preparation comprises tablet, capsule, granule.
5. the traditional Chinese medicinal material raw materials compositions described in any one of claim 1-3 is purposes in the atherosclerotic medicine of preparation control.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510774119.9A CN105343596A (en) | 2015-11-13 | 2015-11-13 | Pharmaceutical preparation for controlling atherosclerosis and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510774119.9A CN105343596A (en) | 2015-11-13 | 2015-11-13 | Pharmaceutical preparation for controlling atherosclerosis and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105343596A true CN105343596A (en) | 2016-02-24 |
Family
ID=55319755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510774119.9A Pending CN105343596A (en) | 2015-11-13 | 2015-11-13 | Pharmaceutical preparation for controlling atherosclerosis and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105343596A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104225286A (en) * | 2013-06-24 | 2014-12-24 | 山东明仁福瑞达制药股份有限公司 | Traditional Chinese medicine preparation for treating hypertension and preventing stroke and preparation method of traditional Chinese medicine preparation |
| CN104435449A (en) * | 2014-12-23 | 2015-03-25 | 青岛市市立医院 | Pharmaceutical composition for resisting atherosclerosis and application of pharmaceutical composition |
-
2015
- 2015-11-13 CN CN201510774119.9A patent/CN105343596A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104225286A (en) * | 2013-06-24 | 2014-12-24 | 山东明仁福瑞达制药股份有限公司 | Traditional Chinese medicine preparation for treating hypertension and preventing stroke and preparation method of traditional Chinese medicine preparation |
| CN104435449A (en) * | 2014-12-23 | 2015-03-25 | 青岛市市立医院 | Pharmaceutical composition for resisting atherosclerosis and application of pharmaceutical composition |
Non-Patent Citations (1)
| Title |
|---|
| 李春梅等: "海带多糖对实验性高血脂鹌鹑的降脂及抗动脉粥样硬化作用", 《中药材》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102048821B (en) | Method for preparing perhexiline pharmaceutical preparation | |
| CN108403882B (en) | Salvia miltiorrhiza composition for treating coronary heart disease and preparation method thereof | |
| CN109966328A (en) | Ellagic acid and the extracting method of chebulinic acid and combinations thereof in a kind of myrobalan | |
| CN102895387B (en) | Kidney-yang-warming medicine composition, and preparation thereof and preparation method thereof | |
| CN104689133A (en) | Pharmaceutical composition for treating myocardial ischemia | |
| TWI678211B (en) | Uses of cistanche tubulosa extract and isoacteoside in protecting muscles | |
| CN107812115A (en) | A kind of Chinese medicine composition for treating diabetes | |
| CN101199806A (en) | Drug for treating laxness, preparing method and quality controlling method thereof | |
| CN105311337B (en) | A kind of Traditional Chinese medicine compound composition and preparation method thereof for treating pulmonary disease | |
| CN101152223B (en) | Use of poplar leaf phenols extract in preparation of medicine for treating cardiovascular disease | |
| CN105343596A (en) | Pharmaceutical preparation for controlling atherosclerosis and its application | |
| KR101934810B1 (en) | Preparation for improving blood circulation comprising oriental medicinal extracts | |
| CN103800736B (en) | A kind of pharmaceutical composition treating hypertensive nephropathy and application thereof | |
| CN102861232A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating hypertension | |
| CN105194355A (en) | Traditional Chinese medicine preparation for treating primary hypertension | |
| CN101810688A (en) | Chinese medicinal composition for treating urinary disease and preparation method thereof | |
| CN104524359B (en) | A kind of Chinese medicine composition, its preparation method and application | |
| CN111821325A (en) | Application of photorhaponticum flower extract | |
| CN109999076A (en) | It is a kind of adjust reverse cholesterol transport Chinese medicine composition and its application | |
| CN116999533B (en) | Heart-nourishing and pulse-activating granule, preparation method thereof and application thereof in antidepressant product | |
| CN103055094B (en) | Traditional Chinese medicine for treating leukemia and preparation method thereof | |
| CN108096270A (en) | A kind of pharmaceutical composition for treating diabetic nephropathy | |
| KR101934811B1 (en) | Preparation for improving blood circulation comprising mixed medicinal extracts | |
| CN108126116A (en) | A kind of preparation process of full rhizoma gastrodiae tablet | |
| CN101926955B (en) | Medicament for treating stomach illness |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160224 |
|
| WD01 | Invention patent application deemed withdrawn after publication |